Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment and our ability to clinically and commercially differentiate our products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility, in amounts and at the times needed; (iii) the availability of raw materials, key components, and equipment, either used in the production of our products and product candidates, or in the use by healthcare professionals of our products and product candidates, including, but not limited to positron emission tomography ("PET”) scanners for PYLARIFY, MK-6240 and NAV-4694; (iv) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 or NAV-4694 as a research tool and under the license agreements through which we have rights to MK-6240 and NAV-4694, and to further develop and commercialize MK-6240 and NAV-4694 as approved products, including the timing for any potential regulatory submissions for these investigational assets; (v) our ability to successfully integrate acquisitions, including of Life Molecular, subject to completion of our acquisition thereof, and Evergreen, including the potential for unforeseen expenses related to integration activities, the accuracy of our financial models, the potential for unforeseen liabilities within those businesses, the ability to integrate disparate information technology systems, retain key talent and create a merged corporate culture that successfully realizes the full potential of the combined organization; (vi) our ability to complete the transaction with SHINE on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory approvals and satisfaction of other closing conditions to consummate the transaction, unforeseen expenses related to the divestiture, and failure to realize the expected benefits of the transaction; (vii) our ability to obtain FDA approval for LNTH-2501, our investigational kit for the preparation of Gallium-68 DOTATOC, which may be used in conjunction with a PET scan to stage and localize gastroenteropancreatic neuroendocrine tumors in adults and children, and approval for PNT2003, and to be successful in the patent litigation associated with PNT2003; (viii) the cost, efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (ix) our ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products; and (x) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).- Tables Follow - Lantheus Holdings, Inc.
Worldwide revenue of $372.8 million in the first quarter 2025GAAP fully diluted earnings per share of $1.02, compared to $1.87 in the first quarter of 2024; adjusted fully diluted earnings per share of $1.53, compared to $1.69 in the first quarter of 2024Free cash flow totaled $98.8 million for the first quarter 2025Closed acquisition of Evergreen Theragnostics early in the second quarter; expect to close on acquisition of Life Molecular Imaging in the coming weeks; and yesterday announced planned divestiture of SPECT businessRecently announced positive data for two MK-6240 pivotal studies; plan to file NDA in the third quarter of 2025Provided updated interim corporate guidance for full year 2025 revenue and adjusted fully diluted earnings per share BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.(Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its first quarter ended March 31, 2025.
Reconciliation of GAAP to Non-GAAP Financial Measures(in thousands, except per share and percent data – unaudited) Three Months Ended March 31, 2025 2024 Net income $72,945 $131,066 Stock and incentive plan compensation 21,198 15,384 Amortization of acquired intangible assets 8,016 9,932 Campus consolidation costs 60 19 Non-recurring fees 2,478 — Gain on sale of assets — (6,254)Strategic collaboration and license costs 5,413 28,000 Investment in equity securities - unrealized loss (gain) 14,862 (60,704)Acquisition-related costs 4,751 788 Other (4,452) 789 Income tax effect of non-GAAP adjustments(a) (15,796) (701)Adjusted net income $109,475 $118,319 Adjusted net income, as a percentage of revenues 29.4% 32.0% Three Months Ended March 31, 2025 2024 Net income per share - diluted $1.02 $1.87 Stock and incentive plan compensation 0.30 0.22 Amortization of acquired intangible assets 0.11 0.14 Campus consolidation costs — — Non-recurring fees 0.03 — Gain on sale of assets — (0.09)Strategic collaboration and license costs 0.07 0.40 Investment in equity securities - unrealized loss (gain) 0.21 (0.86)Acquisition-related costs 0.07 0.01 Other (0.06) 0.01 Income tax effect of non-GAAP adjustments(a) (0.22) (0.01)Adjusted net income per share - diluted $1.53 $1.69 Weighted-average common shares outstanding - diluted 71,461 70,095 (a)The income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP) takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction. Lantheus Holdings, Inc.
The story "Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update" has 1855 words across 35 sentences, which will take approximately 8 - 16 minutes for the average person to read.
Which news outlet covered this story?
The story "Lantheus Reports First Quarter 2025 Financial Results and Provides Business Update" was covered 1 days ago by GlobeNewswire, a news publisher based in China.
How trustworthy is 'GlobeNewswire' news outlet?
GlobeNewswire is a fully independent (privately-owned) news outlet established in 1998 that covers mostly technology news.
The outlet is headquartered in China and publishes an average of 71 news stories per day.
It's most recent story was published 9 hours ago.
What do people currently think of this news story?
The sentiment for this story is currently Negative, indicating that people regard this as "bad news".
How do I report this news for inaccuracy?
You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
